je.st
news
Tag: merck
Merck to Present at the Credit Suisse Healthcare Conference
2013-11-11 21:54:34| Merck.com - Financial News
Dateline City: WHITEHOUSE STATION, N.J Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Peter N. Kellogg, executive vice president and chief financial officer, Merck, is scheduled to present at the Credit Suisse Healthcare Conference, Scottsdale, Arizona on Tuesday, Nov. 12, 2013 at 3:30pm [MST]. Investors, analysts, members of the media and the general public are invited to join a live webcast of the presentation at: http://www.merck.com/investors/events-and-presentations/home.html. About Merck Today's Merck is a global healthcare leader working to help the world be well. Language: English read more
Tags: present
credit
conference
healthcare
Merck provides one-two punch in fight to develop a cure for Hepatitis C
2013-11-03 04:16:36| Biotech - Topix.net
Success in clinical trials makes Merck a real contender in the race to find new treatments for the liver destroying virus... File photo/Merck & Co.
Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
2013-11-02 14:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the presentation of interim data from the ongoing C-WORTHY Study, a Phase II clinical trial evaluating the efficacy and safety of an all-oral regimen combining once-daily MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, with or without twice-daily ribavirin, administered for 12 weeks to treatment-nave, non-cirrhotic pat Language: English Contact: MerckMedia:Pamela Eisele, (908) 423-5042Sarra Herzog, (908) 423-6154orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Analysis: For Merck, bringing cattle feed Zilmax back won't be easy
2013-11-01 10:49:41| Biotech - Topix.net
South Korea plans to begin accepting meat from cattle raised with the muscle-growing supplement early next year, a senior official in the country's food ministry said, opening the door to beef imports after a government risk assessment found the additive could be permitted at certain levels.
Analysis: For Merck, bringing cattle feed Zilmax back won't be easy
2013-10-31 22:07:44| Food - Topix.net
U.S. pharmaceutical giant Merck & Co faces significant challenges bringing its controversial feed additive Zilmax back to market in the United States and Canada, even after a vote of confidence from South Korea on Thursday.
Sites : [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] next »